EU OTC Market Offers “Fragmented Picture” – Consumer Product Execs
This article was originally published in The Tan Sheet
Executive Summary
Opportunities for OTC market growth are being hindered by national-level restrictions in Europe despite recent EU legislative developments favorable to industry, according to European consumer healthcare business leaders
You may also be interested in...
Alli Pioneers EU Centralized Process For Nonprescription Switch
The European Medicines Agency's clearance of GlaxoSmithKline's weight-loss drug alli for nonprescription status across the European Union marks the first success for a centralized Rx-to-OTC switch process
EU Could Save $20 Bil. With Increased Self Medication, AESGP Study Projects
The European Union's 25 member countries would collectively save $20 bil. ($=€.81) annually if 5% of prescription medication purchases were shifted to nonprescription drug purchases, a recent study by the Association of the European Self-Medication Industry (AESGP) states
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC